Top officials at FDA are signaling that the combination products review process is ripe for reform and the 2017 user fee reauthorizations will offer a good opportunity to make needed changes.
Companies and FDA each have frustrations with mismatches between drug and device regulations and with communication challenges between the product centers that lead to inefficiencies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?